Research and Markets: Global Biopharma Outlook 2011: Major US and EU

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/ea71d8/global_biopharma_o) has announced the addition of the "Global Biopharma Outlook 2011: Major US and EU" report to their offering.

The year 2011 and 2012 will be a bonanza for generic companies, as large innovator companies will lose patent exclusivity on prescription drugs worth over $70b in sales. It is imperative to understand how global companies are adapting to this difficult situation, as the challenge is mammoth. There are only two avenues of growth for global pharma companies - Innovation and Emerging markets.

As far as emerging markets are concerned, not all global companies have been able to execute as well as others. There are only a select few companies, that have been able to adapt their product/marketing/pricing strategies to the needs of emerging market and this is reflected by their existing market penetration and on-going growth.

China, which so far has been the darling for global pharma companies, is facing policy pressures and we expect lacklustre growth at least for the next 12 months. This report expects more price cuts from National drug Reimbursement list (NDRL) drugs in China and this report also views the on-going hospital reform with caution. India is growing well and global pharma companies are pursuing different strategies to extract their fair share of the growing market.

This report gives a thorough analysis of the large cap companies - Novartis, Pfizer, Merck, AstraZeneca, Eli Lilly, Bristol Myers Squibb, Novo Nordisk, Sanofi, Glaxo Smithkline and Roche in terms of:

  • The key R&D success and news flow in various therapy areas expected over the next 3 years.
  • Impact of healthcare reforms and patent expires in the major therapeutic classes and companies.
  • The companies that are best poised to grow despite the challenges facing the sector.
  • The companies that are best poised to grab emerging market opportunity.

Each company analysis includes a detailed drug-by-drug pipeline analysis with explanations of how a drug will perform in its therapy area and why. And there is an in-depth look at the current portfolio with generic exposure analysis and sales projections to 2015.

Companies Mentioned

  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sanofi Aventis

For more information visit http://www.researchandmarkets.com/research/ea71d8/global_biopharma_o



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  Europe  North America

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.